• Initial studies show it seems to work as well as liposomal doxorubicin and its main side effect is a low white blood cell count. (cancer.org)
  • The cardioprotective effects of Nar are well documented in the healthy state, in myocardial infarction, and in daunorubicin-, doxorubicin-, and high-glucose-induced cardiotoxicity [ 2 , 12 - 17 ]. (hindawi.com)
  • Anthracyclines, e. g. daunorubicin, doxorubicin, and idarubicin, consist of a tetracycline moiety linked via a glycosidic bond to a sugar residue, usually the aminosugar daunosamine. (lu.se)
  • This phase III trial comparing idarubicin with high-dose daunorubicin as part of induction therapy in AML did not find significant differences in complete remission rates, relapse, or survival. (ascopost.com)
  • A significant interaction between the treatment arm and the FLT3-ITD mutation was found, and high-dose daunorubicin was more effective than idarubicin in patients with FLT3-ITD mutation. (ascopost.com)
  • The two main drugs are cytarabine and daunorubicin, but others such as idarubicin, mitoxantrone and etoposide can be used. (technologynetworks.com)
  • Idarubicin hydrochloride is a DNA-intercalating analog of daunorubicin which has an inhibitory effect on nucleic acid synthesis and interacts with the enzyme topoisomerase II. (nih.gov)
  • Pharmacokinetic studies have been performed in adult leukemia patients with normal renal and hepatic function following intravenous administration of 10 to 12 mg/m 2 of idarubicin daily for 3 to 4 days as a single agent or combined with cytarabine. (nih.gov)
  • Studies of cellular (nucleated blood and bone marrow cells) drug concentrations in leukemia patients have shown that peak cellular idarubicin concentrations are reached a few minutes after injection. (nih.gov)
  • This tiny market cap biotech recently surprised investors with bullish phase 3 trial results for Vyxeos, a nano-scale liposome encased mash-up of the chemotherapy drugs cytarabine and daunorubicin, that sent shares surging 450%, and on Monday, the company updated investors on its timeline for regulatory filings for Vyxeos approval. (foxbusiness.com)
  • In trials, overall survival in secondary acute myeloid leukemia (AML) patients receiving Vyxeos was 9.56 months and that was significantly better than the 5.95 months experienced within the control arm of the study, which was given the standard combination of cytarabine and daunorubicin. (foxbusiness.com)
  • Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. (ox.ac.uk)
  • United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group None. (ox.ac.uk)
  • This research study is studying the combination of venetoclax and chemotherapy as a possible treatment for acute myelogenous leukemia (AML). (dana-farber.org)
  • They cocultured human acute lymphoblastic leukemia (ALL) cell lines with adipocytes and treated them with daunorubicin. (europeanpharmaceuticalreview.com)
  • The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of life of children with acute lymphoblastic leukemia (ALL) and acute lymphoblastic lymphoma (LLy). (centerwatch.com)
  • To determine in a randomized study design whether the incidence and/or severity of acute vincristine-induced peripheral neuropathy can be reduced by decreasing the dosage of vincristine in patients with the high-risk CEP72 TT genotype or by shortening the duration of vincristine therapy in standard/high-risk patients with the CEP72 CC or CT genotype. (centerwatch.com)
  • This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). (cincinnatichildrens.org)
  • A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL Rochester, Minn., Jacksonville, Fla. (mayo.edu)
  • This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. (mayo.edu)
  • A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) Jacksonville, Fla., Rochester, Minn. (mayo.edu)
  • The objective of this study is to assess the safety and tolerability, including the maximum tolerated dose, of ASP2215 in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML). (mayo.edu)
  • A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study) Rochester, Minn. This study seeks adult subjects with R/R Ph+ B-precursor ALL. (mayo.edu)
  • This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. (vicc.org)
  • Daunorubicin is commonly used in the treatment of acute lymphoblastic leukaemia (ALL). (blogspot.com)
  • Cytogenetic studies performed on bone marrow provide important prognostic information and can guide treatment by confirming a diagnosis of acute promyelocytic leukemia (APL). (medscape.com)
  • Cross-sectional study of 36 children with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). (bvsalud.org)
  • Gemtuzumab ozogamicin may be used in combination with daunorubicin and cytarabine for adults with newly-diagnosed AML, or as a stand-alone treatment for certain adult and pediatric patients. (fda.gov)
  • Approval of gemtuzumab ozogamicin in combination with chemotherapy for adults was based on ALFA-0701 (NCT00927498), a multicenter, randomized, open-label phase 3 study of 271 patients with newly-diagnosed, de novo AML aged 50 to 70 years. (fda.gov)
  • Patients were randomized (1:1) to receive induction therapy consisting of daunorubicin (60 mg/m2 on days 1 to 3) and cytarabine (200 mg/m2 on days 1 to 7) with (n=135) or without (n=136) gemtuzumab ozogamicin 3 mg/m2 (up to maximum of one vial) on days 1, 4, and 7. (fda.gov)
  • The first trial, AML-19, was a multicenter, randomized (1:1), open-label phase 3 study in 237 patients comparing gemtuzumab ozogamicin monotherapy to best supportive care (BSC). (fda.gov)
  • Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (vicc.org)
  • The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period. (mayo.edu)
  • GGP modified daunorubicin plus dioscin liposome has suitable particle size , narrow PDI, zeta potential of about -5 mV, long cycle effect, and enhanced cell uptake due to surface modification of GGP making the liposome could enter the inside of the tumor to fully exert its anti- tumor effect. (bvsalud.org)
  • The Company is also conducting a series of studies to evaluate ziftomenib in combination with current standards of care, beginning with venetoclax/azacitidine and standard induction cytarabine/daunorubicin chemotherapy in NPM1-mutant and KMT2A-rearranged newly diagnosed and relapsed/refractory AML (KOMET-007). (abc4.com)
  • Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. (cancer.gov)
  • Aslthough all these drugs have produced good results in preclinical studies of multiple cancers, the outcomes of clinical trials have not been similar. (frontiersin.org)
  • CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. (vicc.org)
  • This study presented an artificial intelligence pipeline of miRNA-based discovery of biomarkers, therapeutic targets, and repositioning drugs that can be applied to many cancer types. (cdc.gov)
  • This study evaluated the in vitro effects of the combination of PKC412 and ara-C or daunorubicin, studying the effect of co-incubation, pre-incubation and sequential incubation of the drugs in patient samples and cell lines. (lu.se)
  • Despite the burden, therefore, ensuring access to essential drugs to claim that sanctions only target political aspects, some control them is vital for health systems to achieve their studies have suggested that they may affect the general objectives and reduce costs. (who.int)
  • however, such factors have not received adequate hardship on health systems and access to drugs, such attention in research studies ( 4 ). (who.int)
  • Early studies with induction including 6-mercatopurine (6-MP) alone or in combination with steroids, methyl-glyoxal guanyl hydrazine and/or methotrexate led to poor results. (nature.com)
  • Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. (doximity.com)
  • They measured the presence of daunorubicin through flow cytometry and liquid chromatography/mass spectrometry, and examined fat cells in bone marrow from children with leukemia. (europeanpharmaceuticalreview.com)
  • The leukemia cells treated with daunorubicin survived and proliferated better in samples that contained adipocytes. (europeanpharmaceuticalreview.com)
  • Mittelman said the study's primary limitation is that the researchers were unable to measure the exact concentration of daunorubicin in the leukemia cells in patients. (europeanpharmaceuticalreview.com)
  • The goals of this study are to help make chemotherapy more effective in treating the patient's leukemia as demonstrated by fewer patients with leukemia minimal residual disease (MRD) while also trying to reduce the amount of body fat that chemotherapy causes the patient to gain in the first month. (cincinnatichildrens.org)
  • 25% blasts by morphology) or at least 1,000/µL circulating leukemia cells in PB confirmed by Flow Cytometry (or other convincing evidence of a B-ALL diagnosis not meeting above criteria following central review by the Study Hematopathologist and Study Chair or Vice-Chair). (cincinnatichildrens.org)
  • Using daunorubicin as a fluorescent marker and vanadate as a positive control compound, a functional flow cytometry method for assessing the ability of a drug to inhibit Pgp-mediated drug efflux from CR1R12 multidrug-resistant cells has been evaluated. (aspetjournals.org)
  • In 1973, daunorubicin (DNR) was shown to increase remission rates from 13 to 58% and to reduce hemorrhage-related mortality after 5 days of therapy relative to 6-MP-based regimens. (nature.com)
  • The purpose of this study is to evaluate the rate of complete MRD response by flow cytometry after 4 weekly doses of daratumumab-hyaluronidase (Day 29) among patients with MRD positive T-ALL in hematologic morphologic complete remission or complete remission with incomplete hematologic recovery. (mayo.edu)
  • This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). (clinicaltrials.gov)
  • The faculty discuss the evolution of induction therapy options for younger patients with AML, as oncologists move from standard 7+3 (cytarabine/daunorubicin) chemotherapy to more personalized approaches. (ascopost.com)
  • The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care. (mayo.edu)
  • GGP modified daunorubicin plus dioscin liposomes inhibit breast cancer by suppressing epithelial-mesenchymal transition. (bvsalud.org)
  • This study demonstrated that this in vitro flow cytometry method is a simple, sensitive, and quantitative tool to assess the capacity of a drug to inhibit Pgp transporters, and is useful for screening or identifying inhibitors of Pgp as well as evaluation of potential for drug interactions. (aspetjournals.org)
  • ADAMTS14 , ARHGAP22 , and EPDR1 expression was not significantly different in survivors versus deceased patients in the study, suggesting they may not be associated with overall survival outcomes. (ajmc.com)
  • This study will also determine the pharmacokinetic (PK) parameters of ASP2215. (mayo.edu)
  • Pharmacokinetic studies and tissue distributions were performed and detected by an ultra-high performance liquid chromatography/mass spectrometry system. (dovepress.com)
  • Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug. (dana-farber.org)
  • This study observed some iodinated radiographic contrast media, diatrizoate, iopromide and iotrolan affected the cellular energetic state and the kinetics of P-gp in drug-sensitive K562 and drug resistant K562/adr cell lines using spectrophotometer and spectrofluorometer. (thescipub.com)
  • You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood. (ehealthme.com)
  • Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet , Mayo Clinic Proceedings , and Nature . (ehealthme.com)
  • This study not only changes our ALL treatment considerations, but also opens the door to study mechanistically how defective repair generates drug-resistant mutations," Zhou said. (sciencecodex.com)
  • Coenzyme Q10 has also been studied as a drug to help relieve muscle problems (including statin-related muscle problems), weakness, cramps, and soreness, but its effectiveness is not clear. (merckmanuals.com)
  • The researchers used whole-exome sequencing to detect the presence of clonal hematopoiesis of indeterminate potential in peripheral blood cells and associated that discovery with coronary heart disease using samples from 4 case-control studies that together enrolled 4,726 participants with coronary heart disease and 3,529 controls. (ascopost.com)
  • Studies in other cancer types have also highlighted ADAMTS14 as a potential player in disease progression , which authors of the current study suggest as a potential novel target in AML. (ajmc.com)
  • The present study showed the remarkable overexpression of the 3 genes in comparison to healthy control at the time of diagnosis," study authors concluded, "which urges further investigation of their implications in disease initiation and perhaps potential use as biomarkers. (ajmc.com)
  • Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with the protocol treatment or procedures, interfere with consent, study participation, follow up, or interpretation of study results. (cincinnatichildrens.org)
  • V. Study the possible associations among patient- and disease-specific factors and family sociodemographic characteristics that mediate treatment outcome. (knowcancer.com)
  • This retrospective study was conducted at the Institute of Hematology & Blood Diseases Hospital, for hospitalized MDS patients diagnosed (WHO 2008 classification criteria) from May 2006 to February 2020. (medscimonit.com)
  • A minimum follow-up of 6 months was required in order to be included in this retrospective study. (springer.com)
  • The patient received induction chemotherapy with daunorubicin and cytarabine and achieved remission, was treated with allogeneic bone marrow transplantation, but died 7 months after initial diagnosis. (ajmc.com)
  • Vanderbilt was the lead site for an NIH-funded, phase 2, multicenter influenza vaccine study in pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients that may lead to a change in the current flu vaccine recommendations in this vulnerable population. (vicc.org)
  • Over the years, characterization and functional studies have revealed the complexity of ROS as signaling molecules that regulate various physiological cellular responses or whose levels are altered in various diseases. (degruyter.com)
  • The change in cellular energetic state was studied using rhodamine B as a probe to estimate mitochondrial membrane potential (ΔΨm). (thescipub.com)
  • The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care. (mayo.edu)
  • The combination of daunorubicin and PKC412 resulted in more synergistic and less antagonistic effects compared to combinations with ara-C, in both patient material and cell lines. (lu.se)
  • Dr. Sallman studies the genetic drivers of myeloid diseases in order to improve prognostication for patients and also to allow for more personalized treatment. (moffitt.org)
  • Steven Mittelman, MD, PhD, associate professor of pediatrics and the division chief of pediatric endocrinology at UCLA Mattel Children's Hospital in Los Angeles, and colleagues sought to examine how obesity might alter the effectiveness of daunorubicin. (europeanpharmaceuticalreview.com)
  • The current case study, published in Heliyon , explored the case of a 37-year-old woman diagnosed with AML after presenting with pancytopenia in the hospital following 2 weeks of general weakness and bone pain. (ajmc.com)
  • Cytogenetic studies performed on bone marrow provide important prognostic information (see the tables below). (medscape.com)
  • This research study will continue to evaluate the side effects of 131I-MIBG when treating children and adults with neuroblastoma. (cincinnatichildrens.org)
  • For some substances there is also a risk assessment made on the basis of concentrations measured in the environment in Sweden and efficacy studies with high quality. (janusinfo.se)
  • Cytarabine is also being studied in the treatment of other types of cancer . (cancer.gov)
  • By colorimetric MTT assay, it was found that contrast media (0-3500 μM) had no effect on both K562 and K562/adr cell viabilities, but in co-treatment with daunorubicin (DNR), diatrizoate decreased cell viability in K562/adr cells by decreasing IC so of DNR from 610.7 ±74.5 nM to 360±108.9 nM. (thescipub.com)
  • This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy can make the patient's ALL more sensitive to chemotherapy and also reduce the amount of body fat gained during treatment. (cincinnatichildrens.org)
  • Daunorubicin (DAN) is mostly used in the treatment of leukaemia and some solid tumour such as glioma. (farmaciajournal.com)
  • EMEND has not been studied for treatment of established nausea and vomiting. (nih.gov)
  • Response criteria for pediatric patients with relapsed AML have also not yet been standardized across study groups, although efforts to do this are currently underway. (haematologica.org)
  • This study involved ALL samples collected from relapsed pediatric ALL patients in the U.S., China and Germany. (sciencecodex.com)
  • Patients in the standard arm (surgery alone) will undergo large en- bloc curative intent surgery will be performed within 4 weeks following randomization. (who.int)
  • The phase IV clinical study is created by eHealthMe based on 151 reports from the FDA, and is updated regularly. (ehealthme.com)
  • In the current study, we evaluated the effect of co-administration of RES and DAN (RES/DAN) in MOLT-4, U266 B1 and Raji cell lines. (farmaciajournal.com)
  • The aim of this study was to explore the kinetics of double strand break (DSB) formation of three ALL cell lines following. (blogspot.com)
  • A study has shown that Adipocytes can absorb and metabolise the chemotherapeutic agent daunorubicin, reducing its ability to kill cancer cells. (europeanpharmaceuticalreview.com)
  • The presence of adipocytes significantly reduced the accumulation of daunorubicin in the ALL cells. (europeanpharmaceuticalreview.com)
  • Targeting AML cells is difficult despite advances in the understanding of its genetic alterations, so a recent study aimed to add potential novel therapeutic targets and gene variants based on RNA sequencing. (ajmc.com)
  • Our phase IV clinical studies alone cannot establish cause-effect relationship. (ehealthme.com)
  • To the best of our knowledge, the effect of Nar in cardiac cell senescence has not yet been studied. (hindawi.com)
  • 3. environmental risk assessments for certain substances based on concentrations measured in the environment in Sweden and effect studies. (janusinfo.se)
  • Initial neuroradiologic studies showed cortical and white matter involvement. (ajnr.org)
  • Study record managers: refer to the Data Element Definitions if submitting registration or results information. (clinicaltrials.gov)
  • Because aging has been demonstrated to be directly related to the occurrence of cardiac disorders, in the present study, the ability of naringenin to prevent cardiac cell senescence was investigated. (hindawi.com)
  • Also, to elucidate the mechanism of cell death, flow cytometry study of Annexin V/PI staining was used. (farmaciajournal.com)
  • Flow cytometry study using Annexin V/Pi showed induction of apoptosis following RES, DAN and RES/DAN. (farmaciajournal.com)
  • It could be proposed for further studies that diatrizoate could be used as MDR identification or MDR imaging and also acted as MDR sensitizing agent in cancer treatments. (thescipub.com)
  • They also studied whether human adipose tissue from cancer patients could metabolise daunorubicin. (europeanpharmaceuticalreview.com)
  • Follow-up studies showed cortical hyperintense lesions on T1-weighted MR images, consistent with cortical laminar necrosis. (ajnr.org)
  • This study sought to identify biomarkers for selecting patients with a high potential for developing invasive carcinoma in the breast with normal histology, benign lesions, or premalignant lesions. (cdc.gov)
  • The second trial, MyloFrance-1, a phase 2, single-arm, open-label study, included 57 patients with CD33-positive AML in first relapse. (fda.gov)